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http://www.nutritionandmetabolism.com/content/10/1/24RESEARCH Open AccessKochujang, fermented soybean-based red pepper
paste, decreases visceral fat and improves blood
lipid profiles in overweight adults
Youn-Soo Cha1*, Soo-Ran Kim1,2, Ji-Ae Yang1,2, Hyang-Im Back1,2, Min-Gul Kim2, Su-Jin Jung2, Won O Song4
and Soo-Wan Chae2,3*Abstract: Health benefits of Kochujang (KCJ) and its bioactive compounds have been reported in several in vitro
and animal studies.
Objective: The aim of this study was to investigate the efficacy of KCJ supplementation on body composition and
blood lipid profiles in overweight adults.
Methods: Sixty overweight men and women with BMI ≥23 kg/m2 and waist-hip-ratio (WHR) ≥0.90 for men and ≥0.85
for women were randomly assigned to a KCJ supplement (n=30, 32 g/day) or placebo (n=30, 32 g/day) group for a
12-week, double-blind, placebo controlled study. We measured anthropometric parameters, serum lipid profiles,
abdominal fat distribution by computerized tomography and calculated the atherosclerosis indices in 53 subjects
(n=26 in KCJ group, n=27 in placebo group) who completed the study.
Results: After 12 weeks, the KCJ group showed a significant reduction in visceral fat (cm2) (p<0.05), although body
weight (kg) and WHR did not change. Serum concentration of triglycerides and ApoB were decreased when
compared to those of the placebo group.
Conclusion: KCJ supplementation (32 g/day) for 12 weeks in overweight adults showed anti-atherosclerotic and
anti-obesogenic effects.
Trial registeration: Clinical trials.gov Identifier: NCT01532375
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The increasing westernized Korean dietary lifestyle,
including frequently eating away from home, has favored
foods that have not been a part of the traditional Korean
diet [1]. The changing consumers’ demand for western
food products and diminished traditional dietary lifestyle
have overlapped with the prevalence of obesity and
obesity-related chronic diseases in Korea [2,3]. Kochujang
(KCJ), a fermented soybean-based red pepper paste, has
long been one of the most representative and commonly* Correspondence: cha8@jbnu.ac.kr; soowan@jbnu.ac.kr
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reproduction in any medium, provided the orused seasonings in Korean cuisine as a sauce, dressing or
seasoning for meat, vegetable dishes, stew and soup.
The KCJ is produced by fermenting powder red peppers
combined with powdered meju (fermented soybean
powder), salt, malt-digested rice syrup, and rice flour for
about six months. The fermentation process extends the
storage period while increasing bioavailability of bio-
active ingredients [4] such as free amino acids, peptides,
alcohols, organic acids, capsaicin and flavonoids [5,6].
KCJ has unique flavors of sweet and hot red pepper
combined with savory soybean protein hydrolyzate and
nucleic acids. In recent years, KCJ has gained its popularity
outside Korea for its taste and health benefits derived from
the several ingredients [7-16] that are produced by the
fermentation process [17-22]. The functional substances
either singularly or in combinations have exhibited anti-
obesogenic, anti-oxidative, and anti-mutagenic properties. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Composition of Kochujang and placebo
supplements (g/day)
Kochujang Placebo
Glutinous rice flour (g) 10.9 -
Powdered red pepper(g) 11.9 -
Malt (g) 5.2 -
Powdered fermented soybeans (g) 4.7 1.1
Spicy flavor powder(g) - 0.1
Perfume of red pepper(g) - 0.3
Honey(g) - 1.4
Caramel pigment(g) - 0.1
Salt (g) 5.2 1.4
Soy sauce (g) 2.1 6.7
Powdered cowpeas (g) 7.5 9.3
Powdered cocoa (g) 2.5 1.4
Powdered vegetable fat(g) - 6.3
Wheat flour(g) - 13.1
Red colors(g) - 1.5
Total wet weight (g) 50 43
Freeze-dried weight (g) 32 32
Energy (kcal) 114 113.1
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models [7-16]. Anti-obesogenic and anti-atherogenic prop-
erties of fermented soy products have been demonstrated
in obese adults [23], possibly through modulation of
hepatic acyl-CoA synthase, carnitine palmitoyltransferase I,
and acyl-CoA oxidase [24]. Recently Ludy and Mattes [25]
reported that hedonically acceptable doses of red pepper
altered thermogenesis and appetite. Their findings are
consistent with previous reports of Reinbach et al [26]
and others [27] who reported the alteration of appetite
and energy balance as a result of red pepper or capsaicin
intake. Lee et al [28] suggested that the alterations could
be through changes in orexigenic and anorexigenic
neuropeptides in hypothalamus.
With the epidemic of obesity and diabetes growing
around the world, KCJ could be potentially effective in
preventing and treating obesity and cardiovascular risks
[16-20] if proven in humans. To date however no clinical
trials of human feeding studies have been reported with
KCJ supplementation. In the present randomized,
double-blind, placebo-controlled clinical trial, we tested
the hypothesis that KCJ supplementation decreases body
fat and improves blood lipid profiles in overweight adults.
Subjects and methods
Study subjects
Healthy men and women volunteers, 19 to 65 years of age,
with BMI ≥23 kg/m2 and WHR of > 0.90 for men and >0.85
for women participated in the study. Excluded from the
study were individuals with (1) lipid metabolic disorders;
(2) >10% changes in body weight in the past 3 months; (3)
cardiovascular disease such as arrhythmia, heart failure,
myocardial infarction, and wearing pacemaker; (4) allergy
or hypersensitivity to any of the ingredients in the test
products; (5) history of reaction to any of the experimental
products or of gastrointestinal diseases such as Crohn’s dis-
ease or gastrointestinal surgery (caecum or enterocele sur-
gery); (6) participation in other clinical trials within the past
2 months; (7) abnormal hepatic liver function, renal disease
such as acute/chronic renal failure, nephrotic syndrome; (8)
use of anti-psychosis drug therapy within 2 months; (9)
laboratory test, medical or psychological conditions deemed
by the investigators to interfere with successful participa-
tion in the study; (10) history of alcohol or substance abuse;
and (11) pregnancy or breastfeeding. All subjects willfully
signed consent to participate in the study after receiving
a detailed explanation of the purpose with research
procedures. The research protocol was approved by the
Institutional Review Board of Chonbuk National University
Hospital's Clinical Trial Center for Functional Food.
Study design
At the onset of the study, each subject was interviewed
for demographic information such as sex, date of birth,age and other lifestyle factors such as past smoking,
drinking and medical histories. The subjects were divided
into a KCJ group (n=30) and a placebo group (n=30) for
the 12-week randomized, double-blind, placebo-controlled
design. The KCJ supplement (32 g/day in pills) was
equivalent to the usual daily intake of 39g wet weight of
KCJ as consumed by Koreans. The KCJ used in the
study was produced by the standardized manufacturing
process and ingredients. Then a single batch KCJ was
lyophilized and made into pills for the entire study
(Imshil Herbal Medicine Co, Imsil, Republic of Korea).
The placebo supplement had the same appearance and
caloric contents without the principal ingredients that
are present in KCJ (Table 1).
The subjects were instructed to maintain their usual
lifestyle and activity levels and avoid other functional
foods or dietary supplements during the 12-week study
period. The subjects visited the clinic every 4 weeks for
a total of five clinic visits (initial screening, and at weeks
0, 4, 8, 12) for monitoring and assessment of compliance
with the protocol. At both the beginning and at the
end of the 12-week intervention; anthropometric and
biochemical parameters, computed tomography, vital
signs, and dietary intakes were measured for both KCJ
and placebo groups. At each visit to the clinic, the
subjects were asked about adverse effects experienced,


















Figure 1 The Flow chart of the study.
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Height was measured using a DS-102 (JENIX, Korea).
Weight, BMI, % body fat, body fat mass, muscle mass,
and WHR were measured using bioelectrical impedance
analysis (Inbody 3.0, Biospace Co., Seoul, Korea). At
weeks 0 and 12, visceral fat, subcutaneous fat, and total
fat were also measured using computed tomography
(CT) scans and visceral to subcutaneous ratios (VSR)
were calculated. Having lumbar vertebrae 4 (L4) as the
center, five different regions between -20 and +20 were
photographed for the abdominal fat area calculation.
Visceral fat and subcutaneous fat were divided after setting
the boundary between the abdominis and the peritoneum.
After computing the numeric value of the total fat and
visceral fat area, the subcutaneous fat area was calculated
by subtracting the area of visceral fat from the total fat.
The proportion was calculated as VSR.
Serum lipid, lipoprotein, atherosclerosis and index in
glycaemic control factor
Fasted blood samples (>12 hr) were used to assess the blood
lipid profiles: total cholesterol (TC), triglycerides (TG),
high-density lipoprotein cholesterol (HDL), low-density
lipoprotein cholesterol (LDL), free fatty acid (FFA),
apolipoprotein AI (ApoA1), apolipoprotein B (ApoB),
fasting plasma glucose, and HbA1c. Blood tests were
conducted with a Hitachi 7600-110 analyzer (Hitachi
High-Technologies Corp., Tokyo, Japan) by standard
methods [23] used in the clinical laboratory of Chonbuk
National University Hospital. Atherosclerosis Indices
(AI) were measured by calculating the ratios (TC-HDL)/
HDL, LDL/HDL and ApoB/ApoA1. The Cardiac Index
(CI) was also calculated by the TC/HDL ratio.
Safety and dietary assessment
Safety measurements for the subjects were taken by elec-
trocardiogram, hematology test and blood chemistry tests,
i.e., white blood and red blood cell counts, hemoglobin,
hematocrit, platelet count, total protein, albumin, alanine
aminotransferase (ALT), aspartate aminotransferase (AST),
blood urea nitrogen (BUN), and creatinine levels [29]. Pulse
and blood pressure were measured at each visit after a
10-minute rest, using the OMRONT4 digital blood
pressure monitor (OMRON Corp., Tokyo, Japan). Each
subject completed a 3-day dietary record for two weekdays
and one weekend day in order to evaluate the energy
intake and diet quality at each clinic visit. The twenty-
four hour dietary intake data were analyzed by one
dietitian throughout the study using Can-Pro 3.0 software
(The Korean Nutrition Society, Seoul, Republic of Korea).
Statistical analysis
Statistical analyses were performed using SAS version 9.0
for Windows (SAS Institute, Cary, NC, USA) and SPSSfor Windows, version 16.0 (SPSS, Chicago, USA). Data
were expressed as the mean and standard errors (SE).
The statical analysis for the main analysis were
performed according to the intention-to –treat principle.
Sample size for the study was based on the mean (SE)
cm2 of visceral fat difference between treatments in the
previous study [30], -7.8 (3.6) cm2 for the experimental
group and +3.9 (6.4) cm2 for the placebo group. It was
estimated to provide 80% power to detect a difference
between groups in visceral fat of 11.7(SD; 20.5) cm2 with
α = .05, using a 2-tailed t-test of the difference between
means. The minimum sample size was determined to 48
participants (24 per group) by calculated, to allow for a
20% dropout rate a total of 60 participants were selected.
Between subjects t-tests were calculated for all
variables measures to determine whether there were
changes associated with the treatment group. Within
each treatment group, paired comparison t tests were
calculated to test whether the change from 0-week to
12-week. Repeated measures mixed model analysis of
variance was performed to see whether there were effects
associated with time (with-person variable), treatment




The sampling and trial profiles are summarized in
Figure 1 along with the number of subjects who
completed the study. Out of 84 subjects pre-screened by
interviews at the onset, 24 subjects did not meet the
selection criteria either in laboratory tests and/or physical
examinations. The remaining 60 subjects were randomly
assigned to the KCJ (n=30) and placebo (n=30) groups.
Four subjects (13%) from the KCJ group and three
subjects (10%) from the placebo group failed to complete
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inadequate intake of the prescribed supplements, and
two subjects voluntarily withdrew due to personal
reasons. A total of 53 subjects (KCJ=26, placebo=27)
completed this study.General characteristics of subjects and dietary assessment
The KCJ and placebo groups were similar in baseline
characteristics (Table 2). Significant differences between
the two groups were observed in dietary intakes (calorie,
carbohydrate, total protein) (Table 3). But no significant
interactions (treatment* time) were observed in the
dietary intake of macro-and micro-nutrients.Body weight and components
Body weight and body composition data of both KCJ
and placebo groups are summarized in the upper part of
Table 4. After 12 weeks of KCJ supplementation, no
significant changes were observed in body weight, BMI,






Age (y) 42.1±1.31 43.0±2.2 0.786
Sex (M/F) b 4/26 3/27 0.688b
Weight (kg) 68.0±1.5 570.2±2.3 0.431
BMI (kg/m2) 26.7±0.4 27.4±0.8 0.383
WHR 0.91±0.005 0.90±0.006 0.242
Visceral fat (cm2) 79.0±5.1 78.3±4.4 0.926
Subcutaneous fat (cm2) 250.5±23.6 249.6±16.0 0.977
SBP (mmHg) 118.1±2.43 119.4±2.2 0.681
DBP(mmHg) 74.4±1.7 75.7±1.5 0.563
Pulse rate(bpm) 68.7±1.9 71.49±1.8 0.216
FPG(mg/dl) 83.3±1.6 81.6±1.5 0.449
HbA1c(%) 5.4±0.1 5.4±0.1 0.894
TC (mg/dL) 192.4±4.7 195.3±6.0 0.649
TG (mg/dL) 118.4±10.2 122.0±12.1 0.703
HDL (mg/dL) 52.0±1.7 52.5±2.1 0.822
LDL (mg/dL) 123.6±4.4 125.12±5.8 0.835
FFA (μEq/L) 612.4±40.5 549.5±33.9 0.239
ApoA1 (g/dL) 1.44±0.03 1.45±0.04 0.770
ApoB (g/dL) 0.86±0.03 0.87±0.04 0.944
1 Values are expressed as means ± SE.
a By independent t test.
BMI body mass index, WHR waist to hip ratio, TC total cholesterol, TG
triglyceride, HDL high density lipoprotein cholesterol, LDL low density
lipoprotein cholesterol, FFA free fatty acid, ApoA1 Apolipoprotein A1, ApoB
Apolipoprotein B., SBP systolic blood pressure, DBP diastolic blood pressure,
FPG fasting plasma glucose.
b Chi-squate test. Statistical analyses were run with or without the men in the
study, and also controlled for the gender as a covariate.Abdominal fat distribution by computerized tomography
Abdominal fat distributions measured by computerized
tomography are shown in the lower part of Table 4.
After 12-week of intervention, the KCJ group showed a
significant reduction in visceral fat area compared to the
placebo group. Furthermore, significant differences were
observed in the visceral fat area from baseline to 12
weeks in both groups. The KCJ group attained a difference
of -4.8cm2 whereas placebo group showed 0.4 cm2
changes in the visceral fat area. Both the change in visceral/
subcutaneous fat ratio decreased from baseline to 12
weeks (p<0.05). Furthermore, a significant interaction
(time * group) were observed in the visceral fat area
(p<0.038).
Blood lipid profiles and atherosclerosis index
As shown in Table 5, the mean difference in TG, ApoA1
and ApoB from baseline to 12 weeks were -17.9, -0.18
and -0.17, respectively in the KCJ group compared with
13.5, -0.14 and -0.12, respectively in the placebo group.
A significant difference in the TG (p=0.026) level was
observed between the two groups. Along with a significant
interaction (time *group) in the difference of TG (p=0.042)
between the two groups.
Apo B level showed no changes in the baseline and
12weeks in either group, however a significant difference
was observed (p=0.049) between the two groups. While
no significant interaction (time*group) were found in
Apo B levels. There was no significant changes or
differences observed in serum TC, HDL, LDL, ApoA1,
ApoB and FFA level between the two groups. The
changes in TC/HDL and (TC-HDL) /HDL ratio (Table 5)
from baseline to 12-week were 0.42 and -0.32, in the
KCJ group compared with -0.10 and -0.04, in the placebo
group, however, these changes were not significant. ApoB/
ApoA1 ratio also showed no changes between the baseline
and 12weeks in either group, but a reduction in the ratio
was observed in the KCJ groups from baseline to 12 weeks.
Safety measurements
The overall safety measures obtained before and after
the intervention indicated no significant changes during
the study (data not shown). The evaluations were also
expanded to laboratory tests, electrocardiogram and vital
signs (blood pressure, pulse) during the subjects’ visits.
Discussion
We hypothesized that KCJ supplementation for 12
weeks would reduce body fat and improve blood lipid
profiles in overweight adults, as demonstrated in animal
studies [20-22]. In this clinical trial, we found no signifi-
cant effects on body weight (kg), body fat (%) or WHR
after 12 weeks of KCJ supplementation. However, CT
scans did reveal significant reductions in visceral fat area
Table 3 Nutrient intakes of the Kochujang and placebo groups at the 0-wk and at 12-wk of the study
Nutrients Kochujang group (n=30) Placebo group (n=30)
0wk 12wk Change* 0wk 12wk Change* P value1 P value2 P value3 P value4
Calorie(kcal/d) 1418.5±53.44 1393.1±92.9 -25.4±115.5 1527.1±58.3 1548.1±79.8 20.9±89.9 0.754 0172 0.028 0.680
Carbohydrate(g/d) 222.8±8.2 208.2±10.3 -14.6±14.3 242.8±11.0 233.3±12.8 -9.5±16.5 0.816 0.070 0.030 0.840
Total protein(g/d) 55.2±2.8 51.2±3.6 -3.9±4.9 60.7±2.2 57.9±5.0 -2.7±5.6 0.867 0.853 0.040 0.823
Total lipid(g/d) 34.7±3.8 34.6±3.8 -0.1±4.7 37.6±1.7 37.3±3.5 -0.3±3.4 0.973 0.955 0.927 0.273
Fiber(g/d) 17.8±0.9 14.6±0.8 -3.2±1.3 19.3±1.1 18.3±1.4 -0.9±1.5 0.261 0.823 0.032 0.273
Cholesterol
(mg/d)
210.5±22.8 249.4±27.5 39.0±27.7 204.3±14.5 280.0±26.4 75.7±31.8 0.385 0.940 0.448 0.429
Na(mg/d) 3,630.4±247.4 3,079.9±225.3 -550.4±305.5 3,665.9±191.2 3697.1±220.4 31.1±280.3 0.168 0.316 0.164 0.170
All values are expressed as means ± SE.
P value1, t-test between changes of the Kocujinag and placebo group : P value2,3,4 time, group and interaction(time*group) effect of two-way repeated measure
ANOVA, after adjusting for age and gender.
* Change = 12 wk – 0wk.
† Paired t-test between 0-wk and 12-wk (P<0.05).
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area of the KCJ group was significantly lower than that
of the placebo (Table 4). In our study we did not control
the lifestyle of the subjects. Apart from the KCJ group,
the placebo group also showed changes in certain
parameter like total fat and subcutaneous fat, however
these changes were not significant. Placebo causes
psychological effects rather than the effect caused by
its ingredients [30].Table 4 Change of body weight,body composition,abdominal
pressure measurements at the 0-wk and 12-wk of the study
Parameters Kochujang group (n=30) Placebo grou
0wk 12wk Change* 0wk
Body weight (kg) 66.6±1.4 66.6±1.4 0.06±0.3 68.5±2.4
Body fat mass (kg) 22.3±0.7 22.0±0.8 -0.3±0.3 24.5±1.6
Body fat (%) 33.4±0.8 33.0±0.9 -0.4±0.4 34.7±.0.9
BMI 26.5±0.4 26.4±0.4 -0.1±0.1 27.4±0.8
WHR 0.91±0.006 0.89±0.009 -0.1±0.1 0.90±0.007
Total fat (cm2) 333.4±29.6 280.6±28.8 -52.8±33.3 324.8±17.9
Visceral fat (cm2) 81.1±5.5 76.2±5.6† -4.8±3.3 78.4±4.8
Subcutaneous
fat (cm2)
252.3±27.1 204.4±26.7 -47.9±33.4 246.4±17.0
VSR 0.37±0.03 0.42±0.03† 0.05±0.02 0.36±0.01
SBP (mmHg) 117.3±2.4 120.3±2.4 2.9±2.4 119.3±2.3
DBP(mmHg) 74.5±1.9 75.4±1.9 0.9±1.9 75.6±1.6
Pulse rate(bpm) 68.8±2.1 68.4±1.6 -0.4±1.3 71.4±1.8
FPG(mg/dl) 84.6±1.6 80.7±1.8 -3.8±1.1 81.6±1.6
HbA1c(%) 5.42±0.03 5.42±0.08 0.007±0.05 5.42±0.01
All values are expressed as means ± SE.
WHR waist to hip ratio, VSR Visceral adipose tissue to subcutaneous adipose tissue
P value1, t-test between changes of the Kocujinag and placebo group : P value2,3,4
ANOVA, after adjusting for age and gender.
* Change = 12 wk – 0wk.
† Paired t-test between 0-wk and 12-wk (P<0.05).Many studies evaluate the effects of specific bioactive
compounds or ingredients such as isoflavones, capsaicine,
capsioids and red pepper power in subjects as adjuncts
with additive effects of dietary intervention in a group of
subjects following a weight loss program. This study took
a different approach. The present study aimed to examine
the biological outcome in humans resulting from the
synergistic effects of functional compounds that constitute
KCJ as a whole food, rather than those of the individualfat area, index in glycaemic control factor and blood
p (n=30)
12wk Change* P value1 P value2 P value3 P value4
68.8±2.5 0.3±0.3 0.577 0.140 0.244 0.439
24.5±1.6 0.0±0.0 0.476 0.480 0.172 0.391
34.6±0.9 -0.1±0.2 0.498 0.351 0.391 0.413
27.5±0.9 0.03±0.0 0.606 0.692 0.248 0.544
0.90±0.01 0.1±0.009 0.351 0.692 0.475 0.274
272.1±12.6† -52.8±6.2 0.998 0.187 0.680 0.972
78.9±4.3 0.4±2.1 0.043 0.001 0.974 0.038
193.2±11.1† -53.2±6.6 0.875 0.107 0.649 0.869
0.44±0.03† 0.08±0.01 0.218 0.001 0.849 0.302
119.7±2.4 0.4±1.5 0.367 0.260 0.706 0.447
76.9±2.1 1.3±1.5 0.880 0.877 0.548 0.813
71.5±2.0 0.1±1.4 0.748 0.506 0.272 0.726
79.6±1.9 -1.9±1.0 0.217 0.056 0.454 0.188
5.47±0.01 0.05±0.06 0.607 0.567 0.673 0.681
ratio.
time, group and interaction(time*group) effect of two-way repeated measure
Table 5 Serum lipid profiles of the Kochujang and placebo groups at the 0-wk and at 12-wk of the study
Parameters Kochujang group (n=30) Placebo group (n=30)
0wk 12wk Change* 0wk 12wk Change* P value1 P value2 P value3 P value41
Total cholesterol(mg/dL) 193.4±5.1 189.8±5.9 -3.6±3.9 196.4±6.3 197.9±5.1 1.5±4.2 0.378 0.047 0.740 0.367
Triglycerides(mg/dL) 112.5±9.1 94.6±5.8† -17.9±8.5 125.6±12.7 139.1±13.8 13.5±12.9 0.049 0.412 0.026 0.042
HDL (mg/dL) 52.3±1.9 51.2±1.9 -1.07±1.5 52.3±2.2 50.9±1.8 -1.32±1.7 0.912 0.100 0.923 0.670
LDL (mg/dL)) 124.9±4.7 122.3±5.2 -0.25±0.14 125.9±6.1 123.6±5.3 -0.15±0.14 0.630 0.188 0.874 0.960
Free fatty acid (μEq/L) 631.8±43.2 604.7±37.4 -27.1±53.9 542.2±34.7 631.9±43.0 89.8±44.0 0.098 0.658 0.669 0.170
ApoA1 (g/dL) 1.44±0.03 1.26±0.03† -0.18±0.03 1.45±0.04 1.31±0.03† -0.14±0.03 0.284 0.002 0.729 0.216
ApoB(g/dL) 0.87±0.03 0.70±0.03† -0.17±0.02 0.88±0.04 0.76±0.04† -0.12±0.02 0.049 0.001 0.540 0.025
Atherosclerosis Indices
TC/HDL 3.8±0.1 3.4±0.2 -0.42±0.2 3.9±0.2 3.8±0.2 -0.10±0.2 0.303 0.935 0.460 0.357
LDL/HDL 2.4±0.1 2.2±0.1 -0.25±0.1 2.5±0.2 2.3±0.2 -0.15±0.1 0.630 0.976 0.671 0.752
(TC-HDL)/HDL 2.8±0.1 2.5±0.2 -0.32±0.2 2.9±0.2 2.8±0.2 -0.04±0.03 0.253 0.975 0.454 0.297
ApoB/ApoA1 0.61±0.02 0.56±0.03† -0.05±0.01 0.61±0.03 0.60±0.03 -0.01±0.02 0.296 0.075 0.240 0.593
All values are expressed as means ± SE.
HDL High-density lipoprotein cholesterol, LDL Low-density lipoprotein cholesterol, ApoA1 Apolipoprotein A1, ApoB Apolipoprotein B, TC/HDL total cholesterol/high
density lipoprotein cholesterol ratio, LDL/HDL low density lipoprotein/cholesterol high density lipoprotein cholesterol ratio, (TC-HDL)/HDL (total cholesterol - high
density lipoprotein cholesterol)/high density lipoprotein cholesterol ratio;
ApoB/ApoA1 Apolipoprotein B/Apolipoprotein A1.
P value1, t-test between changes of the Kocujinag and placebo group : P value2,3,4 time, group and interaction (time*group) effect of two-way repeated measure
ANOVA, after adjusting for age and gender.
* Change = 12 –wk – 0-wk.
† Paired t-test between 0-wk and 12-wk (P<0.05).
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supplementing a traditional food, KCJ, along with the diet
of overweight subjects following a normal diet and
lifestyle. Our subjects did not experience a great degree of
overall weight loss as seen in some studies using higher
doses of bioactive compounds, but did experience a very
significant decrease in visceral fat with concomitant
improvements in risk factors for cardiovascular disease
(Table 4). Visceral adiposity is known to be associated
with an elevated ApoB/ApoA1 ratio with is considered to
be a risk factor for metabolic syndrome [31]. Therefore,
our results showing decreased visceral adiposity and
decreased ApoB is consistent with a protective effect of
KCJ against the development of metabolic syndrome. Our
findings are similar to those in other studies in which
adults (30~60 y of age) who ingested capsinoid (6mg/d)
orally lost abdominal fat and had increased fat oxidation
[32]. In a study of obese college women who consumed
red pepper extracts, the subjects lost both body weight
and body fat [33]. The college women were closely
monitored for their dietary intake through repeated
education and weekly reminders. The close monitoring of
dietary intake is believed to have resulted in changes in
body weight and body fat composition.
Other studies have also reported that daily supplemen-
tation of L-carnitine (300 mg) and isoflavones (400 mg)
for 12 weeks decreased visceral fat [34]. Wu et al (2006)
reported that isoflavon supplementation for one year
resulted in no differences in body mass or body fat, buttrunk fat mass decreased significantly [35]. Apart from
single bioactive components supplement mediated
anti-obesity effect, whole food like fermented soybean
paste doenjang also reported to have anti-obesity effect
in human obese subjects [36]. A Study using fermented
kimchi powder as whole food mixed in animal diet
proved to be beneficial in limiting weight gain in rodent
models [37].
Although statistically insignificant, the changes in
mean energy intake in the KCJ group decreased over 12
weeks while that in the placebo group increased
(Table 3). It is thus possible that capsaicin or other
bioactive components in KJC might have functioned as
appetite suppressants. Serum TG levels decreased in the
KCJ supplemented group in contrast to those of the
placebo group (Table 5). Similar results have been
reported when overweight women were supplemented
with L-carnitine and isoflavon. Capsaicin supplementation
(0.014% wt or 3mg %) with a high fat diet in mice has also
been reported to decrease blood TG, with no changes in
TC levels [38]. In this study, KCJ supplementation
resulted in beneficial effects on TG and ApoB(p<0.05). A
study on healthy adults with Kimchi supplementation
reported no changes in the LDL-C/HDL-C [39], but
supplementation of isoflavon for 12 weeks significantly
decreased the (TC-HDL)/HDL [34]. The profound effect
of KCJ on visceral adiposity and atherogenic indices
observed in the present study might have been mediated
through one or more of the bioactive compounds in KCJ
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peptides from fermented soy [40]. Capsaicin has been
reported to upregulate lipolysis and thermogenesis while
suppressing appetite [25-27]. Isoflavones such as genestein
increases lipid oxidation with upregulated CPT-1 and
activation of PPAR-α [21,41,42].
As the people with obesity and overweight tend to
develop hypertension, the salt content of KCJ (Table 1)
may be of concern. According to KNHANES study [43]
(2010), the daily salt intake of all Koreans (including
children and the elderly) averages 12.1g/day (4,878 mg Na).
In the present study salt intake of the adult subjects from
regular meals (~ 8.5 g/day) and KCJ supplement (~ 6 g/day)
was ~14.5 g/day (5,800 mg Na) which is 16.55% higher than
the mean daily intake by all Koreans. Sodium excretion of
the two groups in the present study, before and after the
intervention, did not show any significant change.
KCJ could be helpful in utilizing it as ketchup or sauce
in western diets. It can be used an a spicy ingredient in
many dishes worldwide. Despite the concern of salt
content of KCJ, we observed the therapeutic benefits of
KCJ in our adult subjects. These findings suggest that
KCJ may have the potential to be developed as a whole
food, nutraceutical or functional supplement for the
management of obesity in some population.
Conclusion
Decreased visceral adiposity and improved atherosclerosis
indices were observed after overweight adults received KCJ
supplementation for 12 weeks. The unique strength of this
study was the observation of biological effect of KCJ, a
whole food, in free-living overweight adults. However, the
mechanisms responsible for these observed effects are yet
to be elucidated.
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